繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Lucid Diagnostics和Front Mobile Health Forge合作,加强急救人员的食道癌筛查

2024-09-03 19:57

Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the execution of a memorandum of understanding (MOU) with Front Line Mobile Health ("Front Line"), a comprehensive medical care provider for first responders. The MOU focuses on the exploration of co-marketing and collaboration opportunities to promote and expand patient access to Lucid's EsoGuard® Esophageal DNA test for the early detection of esophageal precancer, particularly among firefighters. Lucid previously collaborated with Front Line to facilitate its first major directly-contracted #CheckYourFoodTube Precancer Testing Event.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。